Breaking Bottlenecks for the TCR Therapy of Cancer

Immune checkpoint inhibitors have redefined the treatment of cancer, but their efficacy depends critically on the presence of sufficient tumor-specific lymphocytes, and cellular immunotherapies develop rapidly to fill this gap. The paucity of suitable extracellular and tumor-associated antigens in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaissmaier, Lena, Elshiaty, Mariam, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564186/
https://www.ncbi.nlm.nih.gov/pubmed/32937956
http://dx.doi.org/10.3390/cells9092095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564186/
https://www.ncbi.nlm.nih.gov/pubmed/32937956
http://dx.doi.org/10.3390/cells9092095

Ejemplares similares